Insights on Clinical Trials

  1. Transforming Clinical Trial Management 5/5/2026

    See how Vestigo® can transform your study management — streamline workflows, strengthen compliance, and eliminate inefficiencies by adopting a smarter, digital-first approach today.

  2. Navigating The Waters Of Compliance In Clinical Research 5/5/2026

    Strengthen your research processes by adopting secure systems, staying current with regulatory standards, and ensuring your team is consistently trained to manage data responsibly and efficiently.

  3. Here's How FDA's Accelerated Approval Pathway Has Evolved Since '24 5/5/2026

    FDA's accelerated approval guidance kicked off a rebalancing of new drug approval pathways. Since its 2024 release, the agency has been building on it in a few key areas.

  4. Inside March Biosciences' CD5-Targeting CAR-T Approach 5/4/2026

    Fratricide is one of the key reasons T-cell therapies targeting T-cell malignancies have faltered. March's approach aims to solve that with its MB-105 candidate.

  5. Keeping Oncology Programs Moving As Complexity Increases 5/1/2026

    As oncology trials grow more complex, speed depends on clarity. Consistent oversight and shared data help teams make confident decisions faster without losing control.

  6. Scaling Oncology Trials Without Losing Momentum 5/1/2026

    As oncology programs expand, complexity often replaces momentum. Explore how scaling introduces hidden operational challenges and why anticipating continuity early helps teams stay aligned.

  7. Why Early Phase Speed Depends On Oncology Expertise 5/1/2026

    Early phase oncology speed depends on confident, oncology‑specific decisions made upfront. Learn why scientific expertise, realistic planning, and foresight determine whether programs maintain momentum.

  8. Materials Matter: Reframing Raw Material Strategy In Cell And Gene Therapy Development 5/1/2026

    Scaling iPSC-based therapies from lab to CGMP manufacturing demands tightly controlled cryopreservation, risk-based QC, and strategic automation to preserve cell viability, consistency, and regulatory readiness.

  9. How To Establish Strategic Readiness For First-In-Human Trials 4/29/2026

    Most teams realize too late that sequential planning creates delays. FIH readiness depends on aligning IND and clinical strategy early; otherwise, programs risk setbacks that stall execution and timelines.

  10. Sana, Mayo Clinic Advance A New Model For Cell Therapy Delivery In T1D 4/27/2026

    Sana Biotechnology and Mayo Clinic are partnering to standardize delivery of a one-time hypoimmune cell therapy, aiming to scale access and redefine care for type 1 diabetes.